Last quarter (Q4 2023), CytomX Therapeutics's total revenue was $26.61M, an increase of 2709.61% from the same quarter last year. In Q4, CytomX Therapeutics's net income was $837.00K. See CytomX Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 101.21M	$ 101.21M	$ 53.16M	$ 37.31M	$ 100.36M	$ 57.49M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 101.21M	$ 101.21M	$ 53.16M	$ 37.31M	-	-
Operating Expense	$ 107.70M	$ 107.70M	$ 154.50M	$ 153.35M	$ 148.97M	$ 168.38M
Operating Income	$ -6.48M	$ -6.48M	$ -101.33M	$ -116.04M	$ -48.60M	$ -110.89M
Net Non Operating Interest Income Expense	$ 9.84M	$ 9.84M	$ 1.68M	$ 255.00K	$ 1.84M	$ 8.37M
Other Income Expense	$ 30.00K	$ 30.00K	$ -340.00K	$ 83.00K	$ -27.00K	$ -135.00K
Pretax Income	$ 3.32M	$ 3.32M	$ -99.32M	$ -115.87M	$ -46.80M	$ -102.67M
Tax Provision	$ 3.89M	$ 3.89M	-	-	$ -13.91M	$ -427.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -569.00K	$ -569.00K	$ -99.32M	$ -115.87M	$ -32.88M	$ -102.24M
Basic EPS	-	-	-	-	-	$ -2.26
Diluted EPS	-	-	-	-	-	$ -2.26
Basic Average Shares	-	-	-	-	-	$ 45.34M
Diluted Average Shares	-	-	-	-	-	$ 45.34M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 107.70M	$ 107.70M	$ 154.50M	$ 153.35M	$ 148.97M	$ 168.38M
Net Income From Continuing And Discontinued Operation	$ -569.00K	$ -569.00K	$ -99.32M	$ -115.87M	$ -32.88M	$ -102.24M
Normalized Income	$ 6.10M	$ 2.63M	$ -70.76M	-	$ -32.88M	$ -102.24M
Interest Expense	-	-	-	-	-	$ 0.00
EBIT	$ 3.32M	$ 3.32M	$ -99.32M	$ -115.87M	$ -48.60M	$ -110.89M
EBITDA	$ -1.92M	$ -1.92M	$ -96.93M	$ -112.89M	$ -46.03M	$ -108.29M

Currency in USD

CytomX Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing